


**Publications of the Week**
**Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19**

 First Author: Yapeng Su (*pictured, right*) | Senior Author: James Heath (*pictured, left*)  
 Cell | Institute for Systems Biology and UW


The authors present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. They identified a major shift between mild and moderate disease, at which point elevated inflammatory signaling was accompanied by the loss of specific classes of metabolites and metabolic processes.

[Abstract](#) | [Press Release](#)
**Dystrophin Gene Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles**

 First Author: Niclas Bengtsson | Senior Author: Jeffrey Chamberlain (*pictured*)  
 Molecular Therapy | UW Medicine


Researchers explored the persistence of dystrophin expression following rAAV6:CRISPR/Cas9-mediated multi-exon deletion/reframing in systemically injected 2- and 11-week old dystrophic mice, and showed that induction of low dystrophin levels persisted for several months in cardiomyocytes, but not in skeletal muscles, where myofibers remained susceptible to necrosis and regeneration.

[Abstract](#)
[View All Publications](#)
**Local News**
**Dr. Anna Wald Lauded by Infectious Diseases Society**


Fred Hutch



Dr. Anna Wald (*pictured*), a clinical virologist who built a career at Fred Hutch and UW as a leading expert in chronic infections, has been honored by her peers when she delivered the John F. Enders Lecture at the nation's premier gathering of infectious disease scientists. Because of COVID-19, the entire conference was carried out online, with Dr. Wald giving her talk from her Seattle home. [Read More](#)

**Brain and Spine Fluid Proteomics May Hold Alzheimer's Clues**

UW Medicine



A major scientific effort is underway to characterize the proteins in the cerebrospinal fluid to improve diagnostics and clinical monitoring assays, and discover potential therapies, for Alzheimer's disease. Several research labs at the UW School of Medicine and Stanford University are pooling their protein science expertise in this program. Their area – proteomics – is the large-scale analysis of proteins, including their abundance, structure, and function in a biological system.

[Read More](#)
**Sana Biotechnology Announces Acquisition of Oscine**

Sana Biotechnology



Sana Biotechnology, Inc. has announced the acquisition of Oscine Corp., a company developing potentially curative or disease-modifying cell therapies for diseases of the brain and central nervous system. The combination will integrate Oscine's glial progenitor cell program and underlying technologies together with Sana's broader platform and programs. [Read More](#)

**Ultrapotent COVID-19 Vaccine Designed via Computer**

UW Medicine



An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels 10 times greater than is seen in people who have recovered from COVID-19 infections. Designed by scientists at the UW School of Medicine, the vaccine candidate has been transferred to two companies for clinical development. [Read More](#)

**Blood Cell Mutations Confound Prostate Cancer Liquid Biopsy**

UW Medicine



Unrelated mutations, when present in the blood, can lead to false positive results in men with advanced prostate cancer who are undergoing liquid biopsies. Such tests, which look for variants in the cell-free DNA that tumors shed into the blood plasma, help determine suitable treatment options. "You can actually measure what's happening with a patient's tumor by taking a blood draw," said Dr. Colin Pritchard (*pictured*), from UW Medicine. [Read More](#)

**Janssen Phase 3 COVID-19 Vaccine Trial to Begin at KPWHRI**

Kaiser Permanente Washington Health Research Institute (KPWHRI)



KPWHRI will soon enroll volunteers in a phase 3 clinical trial to evaluate a COVID-19 vaccine made by Janssen Pharmaceutical Companies of Johnson & Johnson. Sponsored by the National Institute of Allergy and Infectious Diseases, this is the second phase 3 COVID-19 vaccine trial to be conducted at KPWHRI. Led by Senior Investigator Dr. Lisa Jackson (*pictured*), the team expects to enroll about 150 of the trial's 60,000 volunteers. [Read More](#)

[View All Articles](#) | [Submit an Article](#)
**Upcoming Events in Seattle**

- November 10 10:00 AM **Behind the Scenes of Science**  
Online
- November 17 8:00 AM **Cascadia Innovation Corridor**  
Online
- November 18 8:30 AM **Hindsight 2020 Virtual Symposium**  
Online
- December 5 - 9 8:00 AM **Cell Bio 2020**  
Online
- December 15 - 16 8:00 AM **Showcase Symposium 2020**  
Online

[View All Events](#) | [Submit an Event](#)
**Science Jobs in Seattle**

- Research Technician, Human Genetic Variation**  
Benaroya Research Institute
- Postdoctoral Research Fellow, Molecular Neuroscience**  
Fred Hutch
- Senior/Principal Scientist, Formulation Development**  
Seagen
- Bioinformatics Scientist, Immunology**  
Allen Institute for Immunology
- Scientist, Protein Analytics and Formulation**  
Systemimmune

[View 36 Other Science Jobs](#) | [Submit a Job](#)

**Virtual Exhibit: Immunology**  
See scientific talks and posters from your device



[EXPLORE NOW](#)

 Submit your articles and events by reaching out to us at [info@scienceinseattle.com](mailto:info@scienceinseattle.com).

BROUGHT TO YOU BY


**STEMCELL Technologies**
[Products](#) | [Services](#)
**STEMCELL Science News**
[Free Weekly Updates on Your Field](#)
**The Stem Cell Podcast**
[Interviews and Updates on Stem Cell Science](#)